L-Arginine for Pre-Eclampsia: Timing Changes the Evidence

L-arginine may help prevent pre-eclampsia in some high-risk pregnancies, but the timing is the whole story. A 2025 meta-analysis found that starting supplementation before pre-eclampsia developed was associated with a relative risk of about 0.52—roughly a 48% relative reduction in incidence. That estimate does not mean L-arginine reverses established pre-eclampsia. Trials that started after diagnosis found more limited effects, mainly modest blood-pressure reductions and some attenuation of fetal growth restriction.

This distinction matters for anyone tempted to treat amino acids as interchangeable wellness accessories. Pre-eclampsia begins with problems in placental development long before its recognizable signs—high blood pressure and protein in the urine—appear. A supplement that might support an early biological process cannot necessarily repair the downstream vascular injury after that process has failed.

The prevention signal is real, but preliminary

Makama et al.'s 2025 systematic review and meta-analysis pooled 19 randomized controlled trials of L-arginine in pregnancy, involving 1,992 women. Individual trials enrolled 41 to 672 participants. The prevention subgroup—women enrolled before pre-eclampsia onset—had a relative risk of approximately 0.52 for developing pre-eclampsia.

That is an eye-catching relative result. It is not an absolute-risk result. A relative risk reduction does not tell an individual woman how much her own risk would fall without knowing her baseline risk, which differs sharply between someone with prior severe pre-eclampsia and someone with a lower-risk pregnancy. The published summary available here does not provide a confidence interval for the 0.52 estimate, so readers should not treat the number as a precise forecast.

The trials did not study one uniform population or one standard protocol. They included women with prior pre-eclampsia, chronic hypertension, twin pregnancies, and populations in malaria-endemic regions, where infection may further reduce endogenous L-arginine availability. Oral doses ranged from about 3 to 12 grams per day. Enrollment timing, co-interventions, dose, and underlying risk also varied. Pooling such trials can identify a useful signal, but it cannot tell clinicians the ideal dose, the ideal start date, or whether the same effect applies in a well-nourished high-income setting.

Why early pregnancy and diagnosed disease are different problems

L-arginine is the substrate for endothelial nitric oxide synthase, or eNOS, which produces nitric oxide. Nitric oxide helps blood vessels relax. During early placentation, roughly weeks 10 through 20, nitric-oxide availability may support cytotrophoblast invasion and spiral-artery remodeling. Those remodeled arteries create the low-resistance blood flow a placenta needs.

That gives the prevention finding a plausible biological basis. If low L-arginine availability constrains nitric-oxide production while placental vessels are still remodeling, increasing available substrate could matter. Plausibility is not proof, but it fits the timing of the prevention trials better than a blanket claim that arginine "treats pre-eclampsia."

After diagnosis, the biology is less forgiving. Established pre-eclampsia involves systemic endothelial dysfunction and oxidative stress. The review describes eNOS uncoupling, in which depleted cofactors and the endogenous eNOS inhibitor asymmetric dimethylarginine, or ADMA, can shift the enzyme toward superoxide production instead of nitric oxide. More substrate cannot reliably fix an uncoupled enzyme.

A 2026 study of neutrophil extracellular traps in placental dysfunction and pre-eclampsia adds context, not a treatment test: these inflammatory structures can induce endothelial dysfunction, and the investigators examined circulating markers and deoxyribonuclease activity before delivery. The study supports the idea that established disease involves several reinforcing forms of vascular injury. It does not show that arginine corrects those injuries.

The practical question is not simply "Should I take L-arginine?" It is "Am I still in a prevention window, and does my obstetric clinician think this evidence applies to my risk profile?"

Treatment results do not show disease reversal

The treatment subgroup in the Makama review enrolled women after pre-eclampsia diagnosis. It found modest blood-pressure attenuation and some mitigation of fetal growth restriction, rather than reversal of the disease. These results do not contradict the prevention findings; they suggest that the intervention has different limits once placental dysfunction and systemic endothelial injury are established.

Safety also becomes more consequential in this setting. Women with active pre-eclampsia may receive antihypertensive drugs, while L-arginine can have vasodilatory effects. The review did not systematically control co-administration with antihypertensives, and adverse-event reporting was not uniform. A 2025 retrospective cohort study of singleton pregnancies diagnosed with pre-eclampsia at 36 weeks or earlier found that maternal NT-proBNP, a marker of cardiac stress, had prognostic value for severe maternal adverse outcomes. That does not prove that arginine causes hypotension. It does show why self-directed vasodilator supplementation during active pre-eclampsia is a poor experiment to run at home.

L-citrulline has a better delivery argument, not better clinical evidence

L-citrulline converts to L-arginine and bypasses intestinal and hepatic arginase, which can produce higher plasma L-arginine levels than an equivalent oral L-arginine dose. A 2022 systematic review of randomized endurance-exercise trials describes this nitric-oxide pathway and the pharmacokinetic rationale. It is useful background, not evidence that citrulline prevents pre-eclampsia.

For pre-eclampsia itself, the Makama review found only one L-citrulline randomized trial, with 36 women and no significant effect. A trial that small cannot establish efficacy or confidently rule it out. The result leaves L-citrulline in the "interesting, unproven" column. Superior substrate delivery is not a substitute for patient-outcome data.

Why the pooled estimate could shrink

The prevention result rests on small-to-moderate trials with substantial protocol diversity. A meta-analysis can improve precision over any one small study, but it cannot erase differences in populations, treatment schedules, and co-interventions. The review reported heterogeneity, and its data do not permit a reliable dose-response curve or a firm timing threshold without an individual-participant-data analysis.

Generalizability is another concern. A disproportionate share of the evidence came from malaria-endemic or nutritionally deficient settings. If baseline L-arginine depletion is more common there, the observed relative reduction may overstate the benefit in other populations. Publication bias also remains possible: funnel-plot asymmetry testing was feasible only for outcomes with at least 10 randomized trials, leaving most secondary outcomes and all citrulline outcomes difficult to assess. The broader synthesis also included three non-randomized studies, which carry greater risk of bias than the randomized evidence.

Side effects matter when doses reach the range studied. Nausea, bloating, and diarrhea appear dose-dependent and can become clinically significant at doses of 6 grams per day or more. The trials did not consistently quantify gastrointestinal adverse events, so the tradeoff between sustained dosing and adherence remains uncertain.

Where this fits beside established prevention

L-arginine is not recommended by major clinical guidelines for preventing or treating pre-eclampsia. For women at high risk, low-dose aspirin started before 20 weeks remains the established guideline-supported preventive intervention. The arginine evidence does not support replacing it.

Other proposed preventive approaches show how common this evidence gap is. A 2024 systematic review of randomized trials of probiotics in pregnancy examined pre-eclampsia and related maternal, fetal, and newborn outcomes, while a 2024 review of vaginal progesterone trials evaluated hypertensive disorders of pregnancy. These are separate interventions with separate evidence bases; neither turns a promising mechanistic idea into a definitive prevention strategy. The field still lacks large, decisive trials for many candidates.

What to do with this information

If you are planning a pregnancy or are early in pregnancy and have a major pre-eclampsia risk factor—such as prior pre-eclampsia, chronic hypertension, or a twin pregnancy—bring L-arginine up with your obstetric clinician early, ideally while the placentation window is still open. Ask how your baseline risk, diet, medications, aspirin plan, and local clinical practice change the equation.

Do not self-start L-arginine to treat active pre-eclampsia, and do not swap in L-citrulline because its pharmacology sounds tidier. The best current reading of the evidence is narrower: early L-arginine has a plausible, pooled prevention signal that deserves clinical discussion; treatment evidence is modest; and neither compound has the trial base required for a routine recommendation.